The Foundations of Longitudinal and Adult Learning: A Continuation of Expert Opinion and Data - Interviewing the Specialists in Spinal Muscular Atrophy

The Foundations of Longitudinal and Adult Learning: A Continuation of Expert Opinion and Data – Interviewing the Specialists in Spinal Muscular Atrophy

Faculty Presenters

Gary M. Owens, MD
President
Gary Owens Associated
Ocean View, Delaware

Edmund J. Pezalla, MD, MPH
CEO
Enlightenment Bioconsult, LLC
Daytona Beach, Florida

Crystal M. Proud, MD
Neuromuscular Neurologist
Children’s Specialty Group
Children’s Hospital of The King’s Daughters
Norfolk, Virginia
 
Program Description
Spinal muscular atrophy (SMA) is a common fatal genetic disease and affects Caucasian populations and males at higher rates compared with African American and Hispanic populations or females. A deficiency in SMN protein causes irreversible degeneration of motor neurons, which manifests as progressive muscle weakness resulting in patients having difficulty moving, swallowing, or breathing. SMA can quickly progress to complications affecting breathing and swallowing functions, leading patients to need specialized care with ventilators and/or feeding tubes. Recently approved disease-modifying therapies and emerging treatments have the potential to change SMA treatment protocols as well as improve the quality of life for patients and caregivers. This interdisciplinary discussion will expand upon strategies presented at the AMCP 2020 Nexus conference that managed care professionals and pharmacists can use to collaborate to ensure guidelines for early diagnosis and evaluation of SMA are incorporated into institutional management strategies.

Target Audience: Managed care pharmacists
Type of Activity: Application
Release date: April 30, 2021
Expiration date: April 30, 2022
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:

• Identify current treatment challenges in spinal muscular atrophy (SMA), burden of the disease, and the need for early intervention
• Analyze old and new treatment standards along with the most current data and new clinical trials that aid in the advancement of treatment protocols for patients with SMA
• Construct opportunities for future strategies that will allow increased access to treatment for patients with SMA

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity 0290-0000-21-171-H01-P. The activity is available for CE credit through April 30, 2022.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 

---

Disclosures

Faculty

Gary M. Owens, MD, has the following relevant financial relationships with commercial interests to disclose:

• Consultant: Biogen, Novartis

Crystal M. Proud, MD, has the following relevant financial relationships with commercial interests to disclose:

• Grant/Research Support: AveXis, Biogen
• Consultant: AveXis, Biogen, Genentech
• Speakers Bureau: AveXis, Biogen

Edmund J. Pezalla, MD, MPH, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Kim Simpson, PharmD; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers are used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms